Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Seamless Therapeutics

Company type: Clinical

Main focus: Programmable recombinases

Company stage: Pre-clinical

Diseases: Not disclosed

Genome-editing tool: Programmable designer recombinases

Funding stage: Seed Funding (12.5M)

Location: Dresden, Germany

Website: https://seamlesstx.com/#about_us

Pipeline: Not disclosed

Partners:

Seamless Therapeutics leverages forced evolution to generate target-specific recombinases to address several clinically-relevant conditions. Evolved recombinases hold the potential for safer, more precise, and more efficient genome editing without the need to induced target DNA double-stranded breaks.

Tags

HashtagSeamless Therapeutics

Company: Seamless Therapeutics
close
Search CRISPR Medicine